Logo for AlzeCure Pharma

AlzeCure Pharma Investor Relations Material

Latest events

Logo for AlzeCure Pharma

Status Update

AlzeCure Pharma
Logo for AlzeCure Pharma

Q1 2024

25 Apr, 2024
Logo for AlzeCure Pharma

Q4 2023

27 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from AlzeCure Pharma

Access all reports
AlzeCure Pharma AB (publ), a clinical-stage biopharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease; ACD857, ACD679 and ACD680 for Alzheimer's disease; ACD440 and TrkA-NAM for neuropathic pain; and DBS-10134 (ACD423) for migraine headache.